Andreas Harstrick

Dr. Andreas Harstrick joined Affimed in March 2020 from Molecular Partners in Schlieren, Switzerland where he was the Chief Medical Officer. He has more than 30 years of extensive experience in cancer drug development, including strategic leadership of three global phase 3 programs of new biological entities that culminated in global regulatory approval, and multiple pivotal phase 3 studies.